Low molecular weight heparin
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Cardiology Network |
 Discuss Low molecular weight heparin further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
| WikiDoc Cardiology News |
 Read more about Low molecular weight heparin in the WikiDoc Cardiology News |
| All News Articles |
|---|
| Acute Coronary Syndromes |
| Biomarkers |
| Cardiovascular Imaging |
| CT Surgery |
| Diabetes |
| Electrophysiology |
| General Cardiology |
| Guidelines |
| Health Policy |
| Heart Failure |
| Hypertension |
| Interventional |
| Peripheral Arterial Disease |
| Prevention |
| Valvular Heart Disease |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Phone:617-525-7431
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [3] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
In medicine, low molecular weight heparin (LMWH) is a class of medication used as an anticoagulant in diseases that feature thrombosis, as well as for prophylaxis in situations that lead to a high risk of thrombosis.[1]
Heparin is a naturally-occurring polysaccharide that inhibits coagulation, the process whereby thrombosis occurs (see Heparin: Mechanisms of action). Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of molecular weight from 5000 to over 40,000 Daltons, making up polydisperse pharmacetical grade heparin.[2]
Heparin derived from natural sources, mainly porcine intestine or bovine lung, can be administered therapeutically to prevent thrombosis (see anticoagulation). However, the effects of natural, or unfractionated, heparin can be difficult to predict. After a standard dose of unfractionated heparin, coagulation parameters must be monitored very closely to prevent over- or under-anticoagulation.
Low molecular weight heparins (LMWHs), in contrast, consist of only short chains of polysaccharide. LMWHs are defined as heparin salts having an average molecular weight of less than 8000 Da and for which at least 60% of all chains have a molecular weight less than 8000 Da. These are obtained by various methods of fractionation or depolymerisation of polymeric heparin. They have a potency of greater than 70 units/mg of anti factor Xa activity and a ratio of anti factor Xa activity to anti thrombin activity of >1.5.[3]
Low molecular weight heparin products
Various methods of heparin depolymerisation are used in the manufacture of low molecular weight heparin.[4] These are listed below:
- Oxidative depolymerisation with hydrogen peroxide. Used in the manufacture of ardeparin (Normiflo®)
- Deaminative cleavage with isoamyl nitrite. Used in the manufacture of certoparin (Sandoparin®)
- Alkaline beta-eliminative cleavage of the benzyl ester of heparin. Used in the manufacture of enoxaparin (Lovenox® and Clexane®)
- Oxidative depolymerisation with Cu2+ and hydrogen peroxide. Used in the manufacture of parnaparin (Fluxum®)
- Beta-eliminative cleavage by the heparinase enzyme. Used in the manufacture of tinzaparin (Innohep® and Logiparin®)
- Deaminative cleavage with nitrous acid. Used in the manufacture of dalteparin (Fragmin®), reviparin (Clivarin®) and nadroparin (Fraxiparin®)
Deaminative cleavage with nitrous acid results in the formation of an unnatural anhydromannose residue at the reducing terminal of the oligosaccharides produced. This can subsequently be converted to anhydromannitol using a suitable reducing agent as shown to the left.
Differences between low molecular weight heparin products
Comparisons between LMWHs prepared by similar processes vary. For example a comparison of Dalteparin and Nadroparin suggests they are more similar than products produced by different processes.However comparison of enoxaparin and tinzaparin shows they are very different to each other with respect to chemical, physical and biological properties.
As might be expected products prepared by distinctly different processes are dissimilar in physical, chemical and biological properties.
see references.[5][6][7][8][9]
Differences from unfractionated heparin
Its differences with unfractioned heparin include:
- Average molecular weight: heparin is about 20000 Da and LMWH is about 3000 Da
- Once daily dosing, rather than a continuous infusion of unfractionated heparin
- No need for monitoring of the APTT coagulation parameter
- Possibly a smaller risk of bleeding
- Smaller risk of osteoporosis in long-term use
- Smaller risk of heparin-induced thrombocytopenia, a feared side-effect of heparin.
- The anticoagulant effects of heparin are typically reversible with protamine sulfate, while the effect on LMWH is limited
Clinical uses
Because it can be given subcutaneously and does not require APTT monitoring, LMWH permits outpatient treatment of conditions such as deep vein thrombosis or pulmonary embolism that previously mandated inpatient hospitalization for unfractionated heparin administration
The use of LMWH needs to be monitored closely in patients at extremes of weight or in patients with renal dysfunction. An anti-factor Xa activity may be useful for monitoring anticoagulation. Given its renal clearance, LMWH may not be feasible in patients who have end stage renal disease.
Use in venothromboembolic disease associated with cancer
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than coumarin in reducing the risk of recurrent embolic events.[10]
References
- ↑ Weitz JI (1997). "Low-molecular-weight heparins". N Engl J Med 337 (10): 688-98. PMID 9278467.
- ↑ Linhardt, R.J. Gunay, N. S. (1999). "Production and chemical processing of low molecular weight heparins". Sem. Thromb. Hem. 25 (3): 5-16.
- ↑ European Pharmacopedia Commission (1991). "{{{title}}}". Pharmeuropa 3: 161-165.
- ↑ Linhardt, R.J. Gunay, N. S. (1999). "Production and chemical processing of low molecular weight heparins". Sem. Thromb. Hem. 25 (3): 5-16.
- ↑ Green, D. Hirsh, J. Heit, J. et al (1991). "Low molecular weight heparin: A critical analysis of clinical trials". Pharmacol. Rev. 2: 45-50.
- ↑ Barrowcliffe, T. W. (1995). "Low molecular weight heparin(s)". Br. J. Haematol. 90: 1-7.
- ↑ Donayre C. E. (1996). "Current use of low molecular weight heparins". Semin. Vascul. Surg. 9: 362-371.
- ↑ Hunt, D. (1998). "Low molecular weight heparins in clinical practice". Southern Medical J. 91: 2-10.
- ↑ Fareed, J. Jeske, W. Hoppensteadt, D. Clarizio, R. Walenga, J. M. (1998). "Low molecular weight heparins: Pharmacologic profile and product differentiation". Am. J. Cardiol. 82: 3L-10L.
- ↑ Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003). "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer". N Engl J Med 349 (2): 146-53. PMID 12853587.
External links
nn:Lågmolekylært heparin
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
